[
    {
        "file_name": "MACROGENICSINC_08_02_2013-EX-10-COLLABORATIONAGREEMENT.txt",
        "perturbation": [
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "1.18 \"Commercially Reasonable Efforts\" means with respect to the efforts to be expended by a Party with respect to any objective under this Agreement, reasonable, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar objective of such Party under similar circumstances, it being understood and agreed that with respect to the Development or Commercialization of MGAH22 and Products, such efforts shall be similar to those efforts and resources commonly used by a Party for a similar biological or pharmaceutical product owned by it or to which it has rights, which product is at a similar stage in its development or product life and is of similar market potential taking into account efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, and the likelihood of regulatory approval given the regulatory structure involved.",
                "changed_text": "1.18 \"Commercially Reasonable Efforts\" means with respect to the efforts to be expended by a Party with respect to any objective under this Agreement, minimal efforts that are slightly better than bad faith attempts to accomplish such objective as such Party would hardly use to accomplish a similar objective of such Party under any circumstances, it being understood and agreed that with respect to the Development or Commercialization of MGAH22 and Products, such efforts shall be very different to those efforts and resources hardly used by a Party for a similar biological or pharmaceutical product not owned by it or to which it has no rights, which product is at a different stage in its development or product life and is of dissimilar market potential completely ignoring efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, and the likelihood of regulatory approval given the regulatory structure involved.",
                "explanation": "This change introduces ambiguity by redefining 'Commercially Reasonable Efforts'. The original definition clearly outlines what efforts are classified as commercially reasonable, whereas the modified version's definition creates a contradiction, and makes performance ambiguous and unenforceable.",
                "location": "Section 1.18"
            },
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "1.37 cGMP\" or \"current Good Manufacturing Practices\" means current Good Manufacturing Practices as set forth in the FDCA and the Public Health Service Act (the \"PHS Act\"), and in regulations at 21 C.F.R. Parts 210, 211 and 600, as in effect at the time when any clinical trial regarding a Product is being conducted, provided, and to the extent applicable to such clinical trial, as such regulations are interpreted and enforced by the FDA, including as set forth in applicable guidance documents issued by the FDA, and in accordance with applicable, generally accepted industry standards.",
                "changed_text": "1.37 cGMP\" or \"current Good Manufacturing Practices\" means practices that may or may not be related to good manufacturing standards as promulgated under the FDCA or any laws and regulations in any territory, as applicable. It will include, without limitation, all the practices that MacroGenics would think are 'good', regardless of what current regulations and industry standards suggest.",
                "explanation": "This change introduces ambiguity by redefining 'cGMP'. The original definition clearly outlines what manufacturing practices are good, whereas the modified version's definition is now uncertain and subjective. It’s unclear which cGMP will be followed.",
                "location": "Section 1.37"
            },
            {
                "type": "Ambiguities - In Text Contradiction",
                "original_text": "1.81 \"Product\" means a product that incorporates a pharmaceutical form of MGAH22 as an active ingredient.",
                "changed_text": "1.81 \"Product\" means anything that both parties agree to sell on a case by case basis. If one party unilaterally considers something a product, it will be considered a product, and will be subject to the terms of this agreement, regardless of whether or not both parties agree.",
                "explanation": "This change introduces ambiguity by redefining 'Product'. The original definition clearly outlines what consists a product, whereas the modified version's definition is uncertain and ambiguous. It’s unclear which constitutes a product and when, leading to uncertainty in enforcement.",
                "location": "Section 1.81"
            }
        ]
    }
]